TABLE 3.
Frequency of KIR and HLA class I ligand combination in the control group and COVID-19 patients.
| Hospitalized COVID-19 patients | |||||
|---|---|---|---|---|---|
| All patients (A) n = 200 | Mild (M) n = 93 | Severe (S) n = 107 | Controls (C) n = 195 | Comparisons: p-value, OR (95% CI) | |
| Inhibitory KIR + HLA class I ligand | %F (N+) | %F (N+) | %F (N+) | %F (N+) | |
| 2DL1+C2+ | 55.5 (111) | 62.4 (58) | 49.5 (53) | 55.4 (108) | |
| 2DL2+C1+ | 42.5 (85) | 43.0 (40) | 42.1 (45) | 37.9 (74) | |
| 2DL3+C1+ | 80.0 (160) | 79.6 (74) | 80.4 (86) | 72.3 (141) | |
| 3DL1+Bw4+ | 44.5 (89) | 45.2 (42) | 43.9 (47) | 55.4 (108) | AxC: 0.03, 0.65 (0.43–0.96) |
| 3DL1+Bw4 I80+ | 32.5 (65) | 34.4 (32) | 30.8 (33) | 32.8 (64) | |
| 3DL1+Bw4 T80+ | 18.5 (37) | 15.1 (14) | 21.5 (23) | 27.7 (54) | AxC: 0.03, 0.6 (0.37–1.0); MxC: 0.02, 0.46 (0.24–0.9) |
| 3DL2+A3/A11+ | 25.0 (50) | 26.9 (25) | 23.4 (25) | 35.4 (69) | AxC: 0.02, 0.6 (0.4–0.94); SxC: 0.03, 0.56 (0.3–0.95) |
| 3DL2+A3+ | 11.5 (23) | 15.1 (14) | 8.4 (9) | 26.1 (51) | AxC: 0.0003, 0.37 (0.21–0.63); MxC: 0.037, 0.5 (0.26–0.96); SxC: 0.0004, 0.26 (0.1–0.6) |
| 3DL2+A11+ | 15.0 (30) | 12.9 (12) | 16.8 (18) | 11.3 (22) | |
| 3DL1+Bw4+ and 3DL2+A3/A11+ | 9.5 (19) | 10.8 (10) | 8.4 (9) | 15.4 (30) | |
| 3DL1+Bw4+ and/or 3DL2+A3/A11+ | 60.0 (120) | 61.3 (57) | 58.9 (63) | 75.4 (147) | AxC: 0.001, 0.49 (0.32–0.75); MxC: 0.015, 0.52 (0.3–0.9); SxC: 0.003, 0.5 (0.28–0.77) |
| (3DL1+ Bw4+)- or (3DL2+A3/A11+)- | 50.5 (101) | 50.5 (47) | 50.5 (54) | 60.0 (117) | |
| (3DL1+Bw4+)- and (3DL2+A3/A11+)- | 40.0 (80) | 38.7 (36) | 41.1 (44) | 24.6 (48) | AxC: 0.001, 2.04 (1.33–3.14); MxC: 0.015, 1.93 (1.1–3.3); SxC: 0.003, 2.14 (1.3–3.5) |
| Activating KIR + HLA class I ligand | |||||
| 3DS1+Bw4+ | 19.5 (39) | 18.3 (17) | 20.6 (22) | 21.5 (42) | |
| 2DS1+C2+ | 25.5 (51) | 24.7 (23) | 26.2 (28) | 22.5 (44) | |
| 2DS2+C1+ | 45.0 (90) | 45.2 (42) | 44.9 (48) | 37.9 (74) | |
| 2DS2+A11+ | 7.5 (15) | 5.4 (5) | 9.3 (10) | 4.6 (9) | |
| 2DS5+C2+ | 23.5 (47) | 21.5 (20) | 25.2 (27) | 22.1 (43) | |
| Inhibitory KIR + HLA class I ligand + Activating KIR | |||||
| 3DL1+Bw4+ and 3DS1- | 28.5 (57) | 28.0 (26) | 29.0 (31) | 36.9 (72) | |
| 3DL1+Bw4+ and 3DS1+ | 16.0 (32) | 17.2 (16) | 15.0 (16) | 18.5 (36) | |
| 2DL1+C2+ and 2DS1- | 32.0 (64) | 39.8 (37) | 25.2 (27) | 34.9 (68) | SxM: 0.03, 0.51 (0.23–0.93) |
| 2DL1+C2+ and 2DS1+ | 23.5 (47) | 22.6 (21) | 24.3 (26) | 21.0 (41) | |
| 2DL1+C2+ and 2DS5- | 34.0 (68) | 41.9 (39) | 27.1 (29) | 34.9 (68) | SxM: 0.03, 0.51 (0.28–0.93) |
| 2DL1+C2+ and 2DS5+ | 21.5 (43) | 20.4 (19) | 22.4 (24) | 20.5 (40) | |
| 2DL1+C2+ and 2DS1-2DS5- | 29.5 (59) | 36.6 (34) | 23.4 (25) | 31.3 (61) | SxM: 0.04, 0.53 (0.29–0.98) |
| 2DL1+C2+ and 2DS1+2DS5+ | 19.0 (38) | 17.2 (16) | 20.6 (22) | 17.4 (34) | |
Frequency (%F) of each genotype is expressed as a percentage and defined as the number of individuals having the genotype (N+) divided by the number of individuals studied (n) in the study group;OR, Odds ratio; CI, Confidence interval; Comparisons: AxC, all patients vs. controls, MxC, mild vs. controls, SxC, severe vs. controls, SxM, sever vs. mild.
Values shows significant difference are shown in bold.